AbbVie is a pharmaceutical firm with a strong exposure to immunology (with Humira, Skyrizi, and Rinvoq) and oncology (with Imbruvica and Venclexta). The company was spun off from Abbott in early 2013. The 2020 acquisition of Allergan added several new products and drugs in aesthetics, including Botox. The 2024 acquisitions of Cerevel (neuroscience) and ImmunoGen (oncology) help supplement AbbVie's portfolio.
Company facts
| Company | AbbVie Inc. |
|---|---|
| Symbol | ABBV |
| Exchange | XNYS |
| Sector | Healthcare |
| Industry | Drug Manufacturers - General |
| Market cap | $450.61B (Massive market data, 2026-09-10) |
| Employees | 57,000 |
| Country | United States |
| Website | https://www.abbvie.com |
Trading — AbbVie Inc.
| Last price | $257.12 |
|---|---|
| Change | 0.83% |
| Previous close | $255.00 |
| Day range | $253.92 – $259.61 |
| 50-day average | $254.32 |
| 200-day average | $228.50 |
| Average volume | 6,374,273 |
Price basis: yfinance_daily_bar_close · 2026-09-11T20:31:40.505291+00:00
Valuation and financial health
| Earnings per share | $3.56 |
|---|---|
| Price / book | -75.93 |
| Price / cash flow | 23.10 |
| Enterprise value / EBITDA | 17.45 |
| Enterprise value / sales | 8.00 |
| Debt / equity | -11.93 |
| Current ratio | 0.81 |
| Dividend yield | 2.66% |
| Free cash flow | $18.21B |
| Cash ratio | 0.16 |
| Enterprise value | $514.87B |
Reported 2026-09-10
Earnings
| Report date | 2026-10-30 |
|---|---|
| Session | Pre Market |
| Fiscal quarter ending | Sep/2026 |
| EPS estimate | $3.86 |
| Year-ago EPS | $1.86 |
| Analyst estimates | 6 |
Source: Nasdaq.com public earnings calendar
Other Healthcare companies
Live data
Live quotes, options positioning, insider and congressional filings for ABBV are on the IntelTrends dashboard.